Extent of low-grade dysplasia in Barrett's esophagus: Is it useful for risk stratification?

American Journal of Gastroenterology

Volumn 102, Issue 3, 2007, Pages 494-496

  Falk, Gary W ^a   Goldblum, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER RISK; DISEASE COURSE; DYSPLASIA; ESOPHAGUS BIOPSY; HUMAN; INTESTINE CRYPT; INTESTINE METAPLASIA; PATHOLOGIST; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BARRETT ESOPHAGUS; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL NEOPLASMS; HUMANS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33847323965     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01067.x     Document Type: Review

References (19)

1. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001;120:1630-9.
2. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: Baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
3. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. Gastroenterology 2001;120:1607-19.
4. Sharma P. Low-grade dysplasia in Barrett's esophagus. Gastroenterology 2004;127:1233-8.
5. McArdle JE, Lewin KJ, Randall G, et al. Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. Hum Pathol 1992;23:479-82.
6. Cameron AJ, Carpenter HA. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: A pathological study. Am J Gastroenterol 1997;92:586-91.
7. Van Sandick JW, Van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998;43:216-22.
8. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
9. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: A reaffirmation. Hum Pathol 2001;32:368-78.
10. Offman JJ, Lewin K, Ramers C, et al. The economic impact of the diagnosis of dysplasia in Barrett's esophagus. Am J Gastroenterol 2000;95:2946-52.
11. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: A prospective study. Am J Gastroenterol 2003;98:1931-9.
12. Skacel M, Petras RE, Gramlich TL, et al. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol 2000;95:3383-7.
13. Weston AP, Banerjee SK, Sharma P, et al. p53 protein overexpression in low-grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. Am J Gastroenterol 2001;96:1355-62.
14. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional veterans administration Barrett's cohort. Am J Gastroenterol 2005;100:775-83.
15. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
16. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there a publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
17. Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007;483-93.
18. Dar M, Goldblum JR, Rice TW, et al. Can extent of high-grade dysplasia predict the presence of adenocarcinoma at esophagectomy? Gut 2003;52:486-9.
19. Sharma V, Kim HJ, McLaughlin R. Successful circumferential ablation of Barrett's esophagus with low-grade dysplasia using the Halo360 ablation system: One-year follow-up of the AIM-LGD pilot trial. Gastrointest Endosc 2006;63:AB127.